Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis

References

• Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: east meets west. J Gastroenterol Hepatol. 2020;35(3):380–389. doi:10.1111/jgh.14872
   PubMed Web of Science ®Google Scholar
• Ye Y, Manne S, Treem WR, Bennett D. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflammatory Bowel Dis. 2019;26(4):619–625. doi:10.1093/ibd/izz182
   Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. doi:10.14309/ajg.0000000000000152
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–1461. doi:10.1053/j.gastro.2020.01.006
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB, Lichtenstein GR. The guide to guidelines in ulcerative colitis: interpretation and appropriate use in clinical practice. Gastroenterol Hepatol. 2021;17(4 Suppl 4):567.
   Google Scholar
• Farrell RJ. Biologics beyond anti-TNF agents for ulcerative colitis - efficacy, safety, and cost? N Engl J Med. 2019;381(13):1279–1281. doi:10.1056/NEJMe1910742
   PubMed Web of Science ®Google Scholar
• Augustin M, Costanzo A, Pink A, et al. Real-world treatment patterns and treatment benefits among adult patients with atopic dermatitis: results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey. Acta Derm Venereol. 2022;102:adv00830. doi:10.2340/actadv.v102.3932
   PubMedGoogle Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi:10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• Miranda A, Gravina AG, Cuomo A, et al. Efficacy of ustekinumab in the treatment of patients with Crohn’s disease with failure to previous conventional or biologic therapy: a prospective observational real-life study. J Physiol Pharmacol. 2021;72:567.
   Web of Science ®Google Scholar
• Uchida G, Nakamura M, Yamamura T, Tsuzuki T, Kawashima H. Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a systematic review and meta-analysis. Nagoya J Med Sci. 2023;85(3):402–427. doi:10.18999/nagjms.85.3.402
   PubMed Web of Science ®Google Scholar
• Bressler B, Yarur A, Silverberg MS, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study. J Crohn’s Colitis. 2021;15(10):1694–1706. doi:10.1093/ecco-jcc/jjab058
   Google Scholar
• Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507. doi:10.1111/jcpt.12830
   PubMed Web of Science ®Google Scholar
• Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–1427. doi:10.1093/ibd/izz001
   PubMed Web of Science ®Google Scholar
• Janssen Biotech, Inc. STELARA^® (Ustekinumab) Prescribing Information. Horsham, PA: Janssen Biotech, Inc; 2022.
   Google Scholar
• AbbVie Inc. HUMIRA^® (Adalimumab) Prescribing Information. North Chicago, IL: AbbVie Inc; 2021.
   Google Scholar
• Thunberg J, Bjorkqvist O, Hedin CRH, et al. Ustekinumab treatment in ulcerative colitis: real-world data from the Swedish inflammatory bowel disease quality register. United Eur Gastroenterol J. 2022;10(7):631–639. doi:10.1002/ueg2.12275
   PubMed Web of Science ®Google Scholar
• Hong SJ, Krugliak Cleveland N, Akiyama S, et al. Real-world effectiveness and safety of ustekinumab for ulcerative colitis from 2 tertiary IBD centers in the United States. Crohn's Colitis. 2021;3(1):otab002. doi:10.1093/crocol/otab002
   Google Scholar
• Chiappetta MF, Viola A, Mastronardi M, et al. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021;21(11):1483–1489. doi:10.1080/14712598.2021.1981855
   PubMed Web of Science ®Google Scholar
• Teeple A, Sah J, Mallampati R, Adams C, Waters D, Muser E. Persistence, dosing, and other treatment patterns among Crohn’s disease patients initiating biologics in United States. Crohn’s & Colitis. 2021;3(4):360. doi:10.1093/crocol/otab076
   Google Scholar
• Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled Phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–463. doi:10.1111/bjd.19573
   PubMed Web of Science ®Google Scholar
• Zhdanava M, Ding Z, Manceur AM, et al. Treatment persistence among bio-naïve patients with Crohn’s disease initiated on ustekinumab or adalimumab. Curr Med Res Opin. 2023:1–11. doi:10.1080/03007995.2023.2178148
   Web of Science ®Google Scholar
• Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang TH. An Australian real-world study of treatment persistence of ustekinumab in Crohn’s disease. Biologics. 2021;15:237–245. doi:10.2147/btt.S310076
   PubMed Web of Science ®Google Scholar
• Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis. Ann Gastroenterol. 2021;34(5):612–624. doi:10.20524/aog.2021.0645
   PubMed Web of Science ®Google Scholar
• Dulai PS, Siegel CA, Colombel J-F, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014;63(12):1843–1853. doi:10.1136/gutjnl-2014-307126
   PubMed Web of Science ®Google Scholar
• Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin. Ther. 2018;40(9):1509–1521.e5. doi:10.1016/j.clinthera.2018.07.013
   PubMed Web of Science ®Google Scholar
• Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and early markers of response to biological therapies in inflammatory bowel diseases. J Clin Med. 2021;10(4):853. doi:10.3390/jcm10040853
   PubMed Web of Science ®Google Scholar
• Biemans VBC, Sleutjes JAM, de Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51(9):880–888. doi:10.1111/apt.15689
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Iborra M, et al. Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohn’s Colitis. 2021;15(11):1846–1851. doi:10.1093/ecco-jcc/jjab070
   Google Scholar
• Luttropp K, Dalén J, Svedbom A, Dozier M, Black CM, Puenpatom A. Real-world patient experience of switching biologic treatment in inflammatory arthritis and ulcerative colitis – a systematic literature review. Patient Preference Adherence. 2020;14:309–320. doi:10.2147/PPA.S238843
   PubMed Web of Science ®Google Scholar
• Kane SV, Accortt NA, Macgowan S, Brixner D. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009;29(8):855–862. doi:10.1111/j.1365-2036.2009.03941.x
   PubMed Web of Science ®Google Scholar